The Motley Fool Discussion Boards

Previous Page

Industry Discussions / Biotechnology


Subject:  ++ news for precision onco & tumor agnostic meds Date:  10/15/2020  12:46 AM
Author:  Fuma102 Number:  25442 of 25598

<i The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH), a precision medicine study launched by the ECOG-ACRIN Cancer Research Group and the National Cancer Institute, has found that many patients’ tumors bear genetic abnormalities that can be targeted with existing drugs—approved or experimental.


After its inception five years ago, NCI-MATCH obtained tumor biopsy samples from 5,954 patients whose cancer had progressed on standard treatments or was not curable with available regimens. The researchers then successfully sequenced 5,540 and tried to pair their genetic abnormalities with existing drugs, which were either FDA-approved or investigational in biomarker-defined patient populations.

They found matches for 37.6% of the patients. Because the trial was carried out years ago, the match rate may be even better as more drugs are developed, the researchers figured.

The NCI-MATCH researchers believe their findings confirm the value of tumor gene testing, not only for determining the best treatment plan for patients, but also to provide a roadmap for future precision medicine trials. NCI-MATCH currently has 38 treatment arms aimed at gathering further data on patient responsiveness in different cancer types.

Like I've been saying, I think the "precision oncology" and agnostic meds are going to take a bigger and bigger role in the market.

Full text, actually an interesting read with some good background info:
Copyright 1996-2021 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us